These formulations could be used for a novel personalized immunotherapeutic strategy for the prevention and treatment of endocrine autoimmunity, especially in T1D and APS3v patients harboring the C1858T PTPN22 variant. Here, PTPN22 is linked to type 1 diabetes mellitus.